Mapping Osteosarcoma Biology With CRISPR/Cas: From Gene Function to Therapeutic Targets
Cell Biology International · 2026-11 · 50 (11)
DOI: 10.1002/cbin.70233 ↗At a glance
Übersichtsarbeit in Cell Biology International, published online on 2026-11-11. Written by Amr Ali Mohamed Abdelgawwad El-Sehrawy and 8 co-authors. Institution: Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt. Major MEDLINE topics: Osteosarcoma, CRISPR-Cas Systems, Bone Neoplasms. 99 references.
Abstract (original language)
Osteosarcoma is a highly aggressive primary bone malignancy characterized by rapid proliferation, chemoresistance, and early metastasis. Recent advances in CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR‐associated proteins) genome editing have enabled precise targeting of oncogenes, tumor suppressors, and regulators of epigenetic, metabolic, and signaling pathways, providing new insights into osteosarcoma biology. CRISPR‐mediated knockout of cell‐cycle regulators, including CDK11, impairs proliferation, while restoration of TP53 and suppression of TERT promoter activity inhibits tumor growth. Other line of studies has revealed that chemoresistance mechanisms mediated by ABCB1/MDR1, CD44, ATR, RAD18, and autophagy‐related genes have been effectively reversed through CRISPR interventions, restoring sensitivity to cisplatin and doxorubicin. Furthermore, CRISPR applications in immune modulation, such as PD‐L1 knockout, may enhance antitumor immunity. Importantly, high‐throughput CRISPR screens also may identify essential genes, novel oncogenic drivers, and synthetic lethal targets, thus informing potential precision therapeutic strategies. This review aims to critically summarize CRISPR/Cas‐mediated studies in osteosarcoma, focusing on targeting oncogenes and tumor suppressors, overcoming chemoresistance, modulating immune responses, regulating metabolism and autophagy, and identifying essential genes and vulnerabilities, providing a translational framework for precision therapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Internal Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
- "Tashkent Institute of Irrigation and Agricultural Mechanization Engineers" National Research University, Tashkent, Uzbekistan.
- School of Medical Engineering, Central Asian University, Tashkent, Uzbekistan.
- Western Caspian University, Baku, Azerbaijan.
- Department of General History, Jizzakh State Pedagogical University, Jizzakh City, Uzbekistan.
- Department of Internal Medicine in Family Medicine, Tashkent State Medical University, Tashkent, Uzbekistan.
ORCID profiles: Amr Ali Mohamed Abdelgawwad El-Sehrawy, Ibrokhim Sapaev, Ozodbek Nematov, Rustam Turakulov, Sapaev Bayramdurdi, Nafisa O Turaeva, Aseel Smerat
Cite
APA
El-Sehrawy, A. A. M. A., Sapaev, I., Nematov, O., Turakulov, R., Bayramdurdi, S., Turaeva, N. O., Bainsal, N., Bansal, P., & Smerat, A. (2026). Mapping Osteosarcoma Biology With CRISPR/Cas: From Gene Function to Therapeutic Targets. Cell Biology International, 50(11). https://doi.org/10.1002/cbin.70233
Vancouver
El-Sehrawy AAMA, Sapaev I, Nematov O, Turakulov R, Bayramdurdi S, Turaeva NO, et al. Mapping Osteosarcoma Biology With CRISPR/Cas: From Gene Function to Therapeutic Targets. Cell Biology International. 2026;50(11). doi:10.1002/cbin.70233
BibTeX
@article{ElSehrawy2026,
author = {El-Sehrawy, Amr Ali Mohamed Abdelgawwad and Sapaev, Ibrokhim and Nematov, Ozodbek and Turakulov, Rustam and Bayramdurdi, Sapaev and Turaeva, Nafisa O and Bainsal, Neeraj and Bansal, Pankaj and Smerat, Aseel},
title = {Mapping Osteosarcoma Biology With CRISPR/Cas: From Gene Function to Therapeutic Targets},
journal = {Cell Biology International},
year = {2026},
volume = {50},
number = {11},
doi = {10.1002/cbin.70233}
}
EUVIMED